Regulatory T Cells in Precision Immunotherapy: Mechanistic Insights and Translational Advances of Low-dose Interleukin-2
Life Conflux · 10.03.2026 · 2 (2) · e307
DOI: 10.71321/xk8wzt47 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Conflux, online erschienen am 10.03.2026. Verfasst von Ruiling Feng und 3 weiteren Autor:innen. Die Arbeit nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Regulatory T cells (Tregs) are the central guardians of immune tolerance, safeguarding against autoimmune and inflammatory damage through Foxp3-dependent transcriptional programs. Recent breakthroughs in precision immunotherapy have revived interest in low-dose interleukin-2 (Ld-IL-2), a cytokine-based strategy that selectively expands and activates Tregs via the high-affinity IL-2 receptor (CD25). This review summarizes emerging mechanistic insights into how Ld-IL-2 orchestrates multilevel immune rebalancing and highlights its translational progress from molecular engineering to clinical applications across autoimmune diseases. We integrated recent findings from cellular, metabolic, and systems immunology studies, together with our own multi-center clinical trial data, to outline the dynamic networks linking IL-2 signaling, Treg plasticity, and immune homeostasis. Ld-IL-2 exerts a dose-dependent biphasic effect on the immune system, selectively enhancing Treg survival and function while restraining pathogenic Th17, Tfh, and Teff subsets. Beyond classical STAT5-FOXP3 activation, recent studies reveal that IL-2 reprograms Treg metabolism toward oxidative phosphorylation, stabilizes Foxp3 epigenetic landscapes, and coordinates intercellular communication through exosomal and tissue-resident networks. Innovations in topologically engineered IL-2 variants and sustained-release delivery systems (e.g., polylactic-acid microsphere–exosome composites) further extend the precision and durability of Treg-directed therapy. Clinical evidence from SLE, Sjögren’s disease, and relapsing polychondritis confirms robust immune restoration and favorable safety profiles within defined dose windows. By selectively activating the Treg axis and reprogramming immune homeostasis, low-dose IL-2 represents a paradigm for precision immunotherapy. Integrating molecular engineering and targeted delivery strategies will enable next-generation cytokine therapies to achieve durable immune tolerance across autoimmune and inflammatory disorders.
Zitieren
APA
Feng, R., Huang, B., Zhang, X., & He, J. (2026). Regulatory T Cells in Precision Immunotherapy: Mechanistic Insights and Translational Advances of Low-dose Interleukin-2. Life Conflux, 2(2), e307. https://doi.org/10.71321/xk8wzt47
Vancouver
Feng R, Huang B, Zhang X, He J. Regulatory T Cells in Precision Immunotherapy: Mechanistic Insights and Translational Advances of Low-dose Interleukin-2. Life Conflux. 2026;2(2):e307. doi:10.71321/xk8wzt47
BibTeX
@article{Feng2026,
author = {Feng, Ruiling and Huang, Bo and Zhang, Xia and He, Jing},
title = {Regulatory T Cells in Precision Immunotherapy: Mechanistic Insights and Translational Advances of Low-dose Interleukin-2},
journal = {Life Conflux},
year = {2026},
volume = {2},
number = {2},
pages = {e307},
doi = {10.71321/xk8wzt47}
}
EUVIMED